News | November 06, 2024
Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
USFDA completes PAI of Lupin’s biotech facility in Pune
Subscribe To Our Newsletter & Stay Updated
